Search results
Results from the WOW.Com Content Network
Universal Immunisation Programme (UIP) is a vaccination programme launched by the Government of India in 1985. [1] It became a part of Child Survival and Safe Motherhood Programme in 1992 and is currently one of the key areas under the National Health Mission since 2005.
The rubella vaccine is a live attenuated vaccine. It is available either by itself or in combination with other vaccines. Combinations include with measles (MR vaccine), measles and mumps vaccine (MMR vaccine) and measles, mumps and varicella vaccine (MMRV vaccine). [1] A rubella vaccine was first licensed in 1969. [3]
This is an accepted version of this page This is the latest accepted revision, reviewed on 20 December 2024. Combined vaccine against measles, mumps, and rubella Pharmaceutical compound MMR vaccine MMR vaccine Combination of Measles vaccine Vaccine Mumps vaccine Vaccine Rubella vaccine Vaccine Clinical data Trade names M-M-R II, Priorix, Tresivac, others Other names MPR vaccine AHFS / Drugs ...
Indian Immunologicals, IIL, on 25 November 2023 launched the measles and rubella vaccine 'Mabella' for children. A live-attenuated MR vaccine developed in partnership with Polyvac Institute of Vietnam was launched as part of the 25th celebrations of the IIL division Human Biologicals Institute (HBI) in Udhagamandalam (Ooty), Tamil Nadu.
Rubella infections are prevented by active immunization programs using live attenuated virus vaccines. Two live attenuated virus vaccines, RA 27/3 and Cendehill strains, were effective in the prevention of adult disease. However, their use in prepubertal females did not produce a significant fall in the overall incidence rate of CRS in the UK.
Vaccine combinations (few exceptions), antibiotics, low-dose steroids (less than 20 mg per day), minor infections with low fever (below 38.5º Celsius), diarrhea, malnutrition, kidney or liver disease, heart or lung disease, non-progressive encephalopathy, well controlled epilepsy or advanced age, are not contraindications to vaccination.
The number of measles cases around the world nearly doubled from 2022 to 2023, researchers say, presenting a challenge to efforts to achieve and maintain elimination status in many countries.
Measles & Rubella Initiative (MRI), launched in 2001, is a long-term commitment and partnership among leaders in public health and supports the goal of reducing measles deaths globally by 90% by 2010 compared to 2000 estimates.